Intelligence · Patents
Patents expiring in 2032
Annual patent cliff calendar for 2032 — US pharmaceutical patents by expiration date.
- Patents
- 1,123
Quick answer
1,123 indexed pharmaceutical patents have expiration dates in 2032. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 8246931
Development of a quail embryo model for the detection of botulinum toxin
granted -
US 8247532
Deuterated hepatitis C protease inhibitors
granted -
US 8247598
Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
granted -
US 8247564
Compounds having BETA2 adrenergic receptor agonist and muscarinic receptor antagonist activity
granted -
US 8247550
Certain substituted amides, method of making, and method of use thereof
granted -
US 8247555
Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
granted -
US 8247536
Factor VIII compositions
granted -
US 8247421
5-cyano-4-(pyrrolo [2,3B] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
granted -
US 8247410
Pyrimidine substituted purine derivatives
granted -
US 8247420
Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
granted -
US 8246987
Controlled release composition and method of producing the same
granted -
US 8247183
Compositions and methods for diagnosis and treatment of tumors
granted -
US 8247228
Method of inducing memory B cell development and terminal differentiation
granted -
US 8247403
Benzoxazepine derivatives and use thereof
granted -
US 8247443
Small molecule antagonists of bacterial quorum-sensing receptors
granted -
US 8247433
Process for preparing 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 8247429
Tricyclic compound and pharmaceutical use thereof
granted -
US 8247399
Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
granted -
US 8247563
Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
granted -
US 8252267
DKKL-1 splice product modulators for cancer diagnosis and therapy
granted -
US 8252275
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
granted -
US 8252280
MAPC generation of muscle
granted -
US 8251941
Selective cytopheresis devices and related methods thereof
granted -
US 8252291
Bacteriocins and novel bacterial strains
granted -
US 8252538
MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma
granted -
US 8252574
Pseudoinfectious flavivirus and uses thereof
granted -
US 8252545
Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods
granted -
US 8252737
Antimicrobial peptides and methods of use
granted -
US 8252836
Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease
granted -
US 8252923
Peptidomimetic protease inhibitors
granted -
US 8252541
Sodium channel protein type III α-subunit splice variant
granted -
US 8252926
Process for the preparation of imatinib base
granted -
US 8252937
1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
granted -
US 8252933
2-oxo-1,2-dihydro-quinoline modulators of immune function
granted -
US 8252845
Pterostilbene as an agonist for the peroxisome proliferator-activated receptor alpha isoform
granted -
US 8252839
Compounds and methods for delivery of prostacyclin analogs
granted -
US 8252814
Agents and crystals for improving excretory potency of urinary bladder
granted -
US 8252841
Methods of inhibiting bacterial virulence and compounds relating thereto
granted -
US 8252807
Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
granted -
US 8252787
Protein kinase inhibitors
granted -
US 8252756
Nucleic acid functionalized nanoparticles for therapeutic applications
granted -
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted -
US 8252764
Compositions and methods of use of targeting peptides against placenta and adipose tissues
granted -
US 8252578
Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof
granted -
US 8252791
Purine compounds as cannabinoid receptor blockers
granted -
US 8252550
Targeting poly-γ-glutamic acid to treat Staphylococcus epidermidis and related infections
granted -
US 8252338
Synthetic LDL as targeted drug delivery vehicle
granted -
US 8258106
Immunostimulatory nucleic acid molecules
granted
Frequently asked questions
How many pharma patents expire in 2032?
1,123 published patents in our USPTO index have expiration dates falling in calendar year 2032.